Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVISION Trial in Acute Central Retinal Artery Occlusion
NCT04965038Phase 3Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2022
- Primary completion
- Mar 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase, tissue-plasminogen activator in central retinal artery occlusion (CRAO), sponsored by University Hospital Tübingen. Started Oct 2022; status: terminated.
02
Drugs
tenecteplasetissue-plasminogen activator
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on NCT04965038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965038.